It has transcended the efficacy demonstrated by an experimental pill that managed to completely remit the cancer of 18 patients with leukemia Acute myeloid, very aggressive phase of the disease.
the drug revumeni has achieved very encouraging results in its phase I, according to the scientific journal Nature, with an overall response rate of 53%, as demonstrated by the 60 patients participating in the clinical trial.
In this regard, the rate of complete remission or partial recovery was 30%, while 78% of patients showed elimination of residual disease.
The study, the first in humans, included 68 patients with an average age of 43 years, including children as young as 10 months, and among the types of leukemia suffered by the patients were:
- Acute myeloid (82%)
- Acute lymphocytic (16%)
- Mixed phenotype (2%)
The average mean for the response to treatment was 9.1 months, while the average survival rate of the patients starts from the proofit was 7 months.
What is acute leukemia?
Leukemia is a type of blood cancer characterized by a permanent, abnormal, and disorderly increase in the number of leukocyteswhich generates an ‘invasion’ of these cells in the bone marrow, preventing the development of blood cells, generating a lack of red blood cells and platelets.
Thus, the person suffering from leukemia is exposed to various types of diseases as the body is unable to combat them due to the loss and eventual lack of natural defenses. Types of acute leukemia include:
- Acute lymphocytic leukemia: it is generally a pediatric disease, whose incidence is between 3-5 years of age. It is the most frequent malignant disease of childhood, also appearing during adolescence.
- Acute myeloid leukemia: This type of cancer starts in the bone marrow, and most often quickly spreads to the blood. Sometimes it spreads to other parts of the body, including the lymph nodes, liverspleen, or central nervous system (brain and spinal cord).
- Chronic lymphocytic leukemia: It is the most common leukemia in adults. This is a type of cancer that originates in cells that become certain white blood cells, causing leukemia cells to take longer to accumulate, so many patients may not present symptoms of the disease for years.